Pacific Shuanglin Bio-Pharmacy's Subsidiary Secures Market Approval for Human Coagulation Factor IX Drug

Stock News
Feb 04

Pacific Shuanglin Bio-Pharmacy Co., Ltd. (000403.SZ) has announced that its wholly-owned subsidiary, Guangdong Shuanglin Bio-Pharmaceutical Co., Ltd. (referred to as Guangdong Shuanglin), has received the Acceptance Notice for the market approval application of its Human Coagulation Factor IX drug from the National Medical Products Administration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10